which tested the antibody in 65 HoFH patients already being treated with statins, PCSK9 inhibitors and other drugs like ezetimibe. Adding in Regeneron’s antibody resulted in a 49% drop in ...

The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

US FDA revokes authorization for four COVID antibody drugs Healthcare & Pharmaceuticalscategory· December 23, 2024 Regeneron Pharmaceuticals has settled allegations that it misused a patented ...

Regeneron Pharmaceuticals Inc.’s stock rose 4.9% Tuesday to put it on track for its biggest one-day gain in almost two years, ...

To counter the decline in Eylea sales, Regeneron developed a higher dose of the drug. While the initial ... a bispecific antibody targeting BCMA and CD3, in R/R multiple myeloma that has ...

After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year ...